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Background
Short course antiretroviral (ARV) treatment around deliv-
ery reduces early mother-to-child transmission (MTCT) of
HIV-1 by 35-60 %. However, additional interventions are
required to prevent postnatal transmission through
breastfeeding. We have performed two studies (MITRA
and MITRA PLUS) to investigate the possibility to reduce
MTCT of HIV-1 by prophylactic ARV treatment of infants
or mothers during breastfeeding.
Materials and methods
In the MITRA study HIV-1 infected pregnant women were
treated during late pregnancy and for one week after deliv-
ery with two ARV drugs, zidovudine (ZDV) and lamivu-
dine (3TC). Infants were treated with these drugs for one
week after birth and then with 3TC alone during breast-
feeding (maximum 6 months). In the MITRA PLUS study
the HIV-1 infected mothers were treated with three ARV
drugs, ZDV+3TC+nevirapine (NVP) during late pregnancy
and breastfeeding (NVP was replaced by nelfinavir for
mothers with adverse reactions on NVP). Treatment of the
mothers was stopped at six months except for those who
needed ARV treatment for their own health. In both stud-
ies mothers were counseled on exclusive breastfeeding
and encouraged to stop at six months. Transmission of
HIV-1 was analyzed using the Kaplan Meier survival tech-
nique.
Results
In the MITRA study 398 infants were included in the trans-
mission analysis. The cumulative proportion of HIV-
infected infants was 3.8% (95%CI 2.0%-5.6%) at 6 weeks
and 4.9% (95%CI 2.7%-7.1%) at 6 months of age. In the
MITRA PLUS study there were 440 infants included in the
transmission analysis. The proportion of HIV-1 infected
infants was 4.1% (95%CI 2.1%-6.0%) at 6 weeks and
5.0% (95%CI 3.2%-7.0%) at 6 months. The median time
of breastfeeding was 18 weeks in the MITRA study and 24
weeks in the MITRA PLUS study. NVP-related skin reac-
tions occurred in 24 (5.5%) of 433 NVP-treated women,
of whom 6 had Steven Johnson syndrome. All women
with skin reactions had CD4 cell counts > 200/mm3.
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The HIV-1 transmission rates at 6 weeks and 6 months
after delivery in the MITRA and MITRA PLUS studies were
similar and are among the lowest reported in a breastfeed-
ing population in sub-Saharan Africa. The strategy used in
the MITRA PLUS study is the obvious choice for mothers
who need ARV treatment for their own health whereas
prophylactic ARV treatment of the infant during breast-
feeding could be a possible choice for mothers with high
CD4 cell counts.Page 2 of 2
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